<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-05-26">May 26, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Yong</forename><surname>Liu</surname></persName>
							<email>liuyong@zjcc.org.cn</email>
							<affiliation key="aff0">
								<orgName type="department">Surgical Department of Colorectal Cancer</orgName>
								<orgName type="institution">Zhejiang Cancer Hospital</orgName>
								<address>
									<addrLine>Zhejiang Province</addrLine>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Charité Comprehensive Cancer Center</orgName>
								<orgName type="institution">Labor AG Keilholz</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefano</forename><surname>Meucci</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Charité Comprehensive Cancer Center</orgName>
								<orgName type="institution">Labor AG Keilholz</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Liming</forename><surname>Sheng</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Radiotherapy</orgName>
								<orgName type="institution">Zhejiang Cancer Hospital</orgName>
								<address>
									<addrLine>Zhejiang Province</addrLine>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Keilholz</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Charité Comprehensive Cancer Center</orgName>
								<orgName type="institution">Labor AG Keilholz</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-05-26">May 26, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">60A35B81CE4E90C2E445DD3FF58CF4E6</idno>
					<note type="submission">Received: January 17, 2017 Accepted: May 16, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>colorectal cancer</term>
					<term>KRAS mutation</term>
					<term>BRAF mutation</term>
					<term>circulating tumor cells</term>
					<term>clinical stage</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>As predictive markers for anti-EGFR therapy, KRAS and BRAF mutations are routinely detected in primary and metastatic colorectal cancer (CRC) cells, but seldom in circulating tumor cells (CTCs).</s><s>Detecting mutations in CTCs could help explain mutational differences between tumor cells at local sites and distant metastases, thereby improving treatment outcomes.</s><s>Here, we conducted a systematic review and meta-analysis to compare KRAS and BRAF mutations in paired CTCs and primary tumors from CRC patients, to detect any possible discordance.</s><s>A total of 244 CRC patients from nine studies were included.</s><s>Our subgroup meta-analysis demonstrated that the total odds ratio for mutations in CTCs was only 55% of that in primary tumors in the stage IV subgroup.</s><s>We also found low heterogeneity among studies and differences in mutations between CTCs and primary tumors in the stage IV subgroup (I 2 = 0%, P = 0.01).</s><s>We observed a higher frequency of KRAS mutations in CTCs than in primary tumors at early stages (I + II), a similar frequency in stage III, and a lower frequency in stage IV.</s><s>There were also differences among the Epcam-targeted CTC enrichment, PCR-based mutation profiling, and ≥ 3 CTCs enriched (I 2 = 0%, P = 0.03) subgroups.</s><s>These finding indicate mutational discordance between CTCs and primary CRCs, particularly in the stage IV and KRAS subgroups.</s><s>We suggest large-sample studies stratified by clinical stage and KRAS subtype are urgently warranted to accurately evaluate mutational variations in CTCs compared to primary and metastatic CRC cells.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide <ref type="bibr" target="#b0">[1]</ref>.</s><s>The endothelial growth factor receptor (EGFR) relative pathway regulates the expression of genes involved in the proliferation, angiogenesis, and metastasis of CRC cells <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>Mutations in the Kirsten rat sarcoma (KRAS) viral oncogene have been reported to be present in 30-40% of CRC patients and to correlate with clinical resistance to anti-EGFR drugs in metastatic CRCs <ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref>.</s><s>Indeed, KRAS mutations are a predictive biomarker for anti-EGFR resistance in metastatic CRC (mCRC) <ref type="bibr" target="#b7">[7,</ref><ref type="bibr" target="#b8">8]</ref>.</s><s>Furthermore, KRAS mutations in primary tumors correlate with poor prognosis and short term survival <ref type="bibr" target="#b9">[9,</ref><ref type="bibr" target="#b10">10]</ref>.</s><s>Therefore, only CRC patients with wild type KRAS usually receive anti-EGFR therapy <ref type="bibr" target="#b11">[11,</ref><ref type="bibr" target="#b12">12]</ref>.</s><s>BRAF (proto-oncogeneB-Raf), also part of the EGFR pathway, is also mutated in 10% of mCRC patients <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b13">13,</ref><ref type="bibr" target="#b14">14]</ref>.</s><s>In addition, retrospective analyses have shown that wild-type BRAF is necessary for successful response to anti-EGFR therapies in metastatic CRCs (mCRCs) <ref type="bibr" target="#b13">[13,</ref><ref type="bibr" target="#b15">15]</ref>.</s><s>KRAS and BRAF mutations together serve as predictive markers for anti-EGFR therapies <ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b17">17]</ref>.</s></p><p><s>Recently, studies exploring the correlation between KRAS mutational status in primary and metastatic tumors of CRC patients revealed intra-tumor heterogeneity or mutation discordance after anti-EGFR treatment failure in patients with wild type KRAS <ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref>.</s><s>Furthermore, other studies suggested that resistance to anti-EGFR therapy</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Meta-Analysis</head><p><s>possibly stemmed from selection of preexisting minor sub-clones harboring mutations <ref type="bibr" target="#b5">[5,</ref><ref type="bibr" target="#b11">11]</ref>.</s><s>The mutational status of metastatic tumors does not always correspond with those in primary lesions.</s><s>Circulating tumor cells (CTCs) can carry mutant variants from local tumor sites to distant metastases <ref type="bibr" target="#b22">[22]</ref>.</s><s>Recent improvements in DNAsequencing technology have allowed high resolution by exploring sub-clone heterogeneity between primary and metastatic tumors <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>, but recovering sufficient tumor cells is still challenging to exceed the available sequencing analytical platforms <ref type="bibr" target="#b25">[25]</ref>.</s><s>Genotyping of CTCs might improve the monitoring of response to targeted EGFR therapies by identifying genomic profiles and predicting disease metastasis prior to clinical progression <ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b27">[27]</ref><ref type="bibr">[28]</ref><ref type="bibr" target="#b28">[29]</ref>.</s><s>High concordance in mutations has been observed between CTCs and primary tissues in mCRC patients and the presumption that discordance exists in both wild type and mutation sub-populations has been challenged <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>.</s><s>It is also possible that mutated sub-clones in primary tumors shed as CTCs into peripheral blood were not present in the tumor tissues used for genomic analyses <ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>.</s><s>On the other hand, some studies have detected mutations in CTCs at the sub-clone level by deep sequencing of primary tumor tissues <ref type="bibr" target="#b28">[29]</ref>.</s><s>However, based on genotype and phenotype profiling, accurate detection of the mutational status of CTCs is still challenging <ref type="bibr" target="#b38">[39]</ref>.</s><s>Here, we tested for KRAS and BRAF mutations in CTCs and paired primary CRCs.</s><s>We also investigated genetic heterogeneity between CTCs and primary tumors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head><p><s>The protocol of our system review was published in PROSPERO: CRD42016042107</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Search strategy</head><p><s>The identification of potentially relevant studies was performed through a comprehensive and systematic search in PubMed, EMBASE, Web of Science Databases, and Google Scholar by using the following keywords "colorectal cancer", "circulating tumor cells" and "mutation".</s><s>Searching details: "neoplastic cells, circulating" [MeSH Terms] OR ("neoplastic" [All Fields] AND "cells" [All Fields] AND "circulating" [All Fields]) OR "circulating neoplastic cells" [All Fields] OR ("circulating" [All Fields] AND "tumor" [All Fields] AND "cell" [All Fields]) OR "circulating tumor cell" [All Fields] AND ("colorectal neoplasms" [MeSH Terms] OR ("colorectal" [All Fields] AND "neoplasms" [All Fields]) OR "colorectal neoplasms" [All Fields] OR ("colorectal" [All Fields] AND "cancer" [All Fields]) OR "colorectal cancer" [All Fields]) AND "mutation" [MeSH Terms] OR "mutation" [All Fields].</s><s>The latest search was updated on September 30, 2016.</s><s>Bibliographies of eligible studies, review articles, the reference lists of each selected study, and other relevant publications were also reviewed to identify all potentially relevant studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inclusion and exclusion criteria</head><p><s>To qualify as relevant, a study had to fulfill the following criteria: (1) circulating tumor cells were enriched and isolated from CRC patients; (2) KRAS and BRAF mutations had to be present in CTCs and primary tumors;</s></p><p><s>(3) the correlations of KRAS mutation in CTCs and paired primary tissues were assessed; (4) the correlations of KRAS mutation in CTCs and paired primary tissues based on treatment outcome (progression or stable) were assessed; <ref type="bibr" target="#b5">(5)</ref> the correlations of BRAF mutation in CTCs and paired primary tissues were assessed; <ref type="bibr" target="#b6">(6)</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data extraction and quality assessment</head><p><s>Two investigators independently screened the studies and extracted the data from included studies by using standard data abstraction forms.</s><s>For each study, relevant data were compiled as follows: name of first author, year of publication, total number of patients included, patients' gender, tumor location (colon/rectum), clinical stage, time of blood sample draws, number of patients with CTCs detected, cutoff number of CTCs, enrichment method and antibody staining of CTCs, number of mutations in CTCs, tissue samples, and in both CTCs and tissue samples combined, subtype mutation of CTCs, methods for mutation detection, tumor status (stable vs progression), and NOS score.</s><s>The mutational status of paired CTCs and tumor tissue samples from each patient along with clinical data were evaluated.</s><s>Then the data from a total of nine qualifying studies were used for further analysis.</s><s>The quality of each study was independently assessed by two investigators using the Newcastle-Ottawa Scale (NOS) <ref type="bibr" target="#b39">[40]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>Data were presented as odds ratio (OR) with its 95% confidence interval(CI) to show the agreement of KRAS and BRAF mutation in paired CTCs and primary tumor samples while risk ratios (RR) at 95% CI were presented to show the agreement of KRAS mutation in paired CTCs and tissue samples based on tumors status (stable or progression).</s><s>The individual OR and RR were combined into pooled ORs and RRs, and initial analyses were performed with a fixed effect model assuming homogeneity in the individual studies.</s></p><p><s>Heterogeneity was evaluated by Q-test and I 2 test.</s><s>When statistically significant heterogeneity among the studies was found by Q-test (P &lt; 0.05) or I 2 &gt; 50%, subgroups were classified by gene subtype, stage, and CTC enrichment, with isolation approach stratification or random effect models being applied for further meta-analysis.</s><s>Otherwise, the fixed effects model was adopted.</s><s>Sensitivity analyses were conducted to identify whether results of the metaanalysis were affected by exclusion of any individual study and to testify the reliability of the conclusions.</s><s>All P values were 2-sided and all analyses were performed using Review Manager 5.3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overview of included studies and quality assessment</head><p><s>From 317 studies retrieved, nine studies that focus on comparing CTC-related mutations with paired tumor tissue of CRCs were included for systematic review (See Figure <ref type="figure" target="#fig_0">1</ref>, Table <ref type="table" target="#tab_1">1</ref>).</s><s>Table <ref type="table" target="#tab_1">1</ref> summarizes details as name of first author (year of publication), total number of patients included, gender, tumor location, clinical stage, time of blood sample draws, number of patients with CTCs, cutoff number of CTCs, enrichment method and antibody staining of CTCs, number of mutation in CTCs, tissue samples, and in both CTCs and tissue samples combined, subtype mutation of CTCs, methods for mutation detection, tumor status, and NOS score.</s><s>According to the NOS quality assessment, all the selected studies have high quality with a median score of 8.11 stars and were thus subject to further meta-analyses.</s><s>Among the total 315 CRC patients, 181 (57.46%) were males and 134 (42.54%) females, with 228 (72.38%) colon carcinomas and 87 (27.62%) rectal carcinomas.</s><s>Among 315 CRC patients, KRAS and BRAF mutations were detected in CTCs and primary tumors from 244 CRC patients.</s><s>KRAS codon12 and codon13 mutations were detected in 28.27% (69/244) and 5.73% (14/244) of the cases, separately, while BRAF  ).</s><s>The concordance of KRAS mutation in CTCs with paired primary tissues of CRCs was compared in all nine studies, but only four studies were evaluated for BRAF mutation of CTCs, three studies were analyzed for KRAS mutation of CTCs with tumor status, and one study assessed mutations among primary tumors, CTCs, and metastatic lesions <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlation of KRAS mutation in paired CTCs and primary tumors</head><p><s>We summarized the data from all nine studies based on KRAS mutation with stage and codon subgroup stratification (See Table <ref type="table" target="#tab_2">2</ref>).</s><s>From the results calculated by McNemar Test and Kappa value, significant discordance (McNemar value &lt; 0.001 for codon12+13 and codon12, 0.289 for codon13) and poor agreement (Kappa value 0.377 for codon12+13, 0.397 for codon12 and 0.476 for codon13) of mutations in paired CTCs and primary CRC tumors were observed in the stage IV subgroup.</s><s>Conversely, high concordance and better agreement between those two study populations (McNemar value 0.687 for codon12+13 and 0.500 for codon12, Kappa value 0.744 for codon12+13 and 0.913 for codon12) were observed in the stage III subgroup.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pooled data analysis of KRAS mutation in paired CTCs and primary tumors (stage I-IV)</head><p><s>With reference to stage I-IV CRC patients, the odds ratio (OR) of paired CTCs and tumor tissues was 0.87 (95% CI; 0.60, 1.26) for KRAS codon12+13 mutation, 0.77 (95% CI; 0.51, 1.14) for KRAS codon12 mutation, and 1.32 (95% CI; 0.53, 3.29) for KRAS codon13 mutation (see Figure <ref type="figure" target="#fig_2">2</ref>).</s><s>No heterogeneity or discordance between studies was observed for three KRAS sub-type mutations in CRC patients (I 2 = 27%, test for overall effect P = 0.45 for codon12+13, I 2 = 0%, P = 0.19 for codon12 and I 2 = 0%, P = 0.55 for codon13).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pooled data analysis of KRAS sub-type mutation in paired CTCs and primary tumors (stage IV)</head><p><s>With reference to KRAS sub-type mutation in stage IV CRC patients, high homogeneity (all I 2 = 0%) between studies and pooled ORs was observed with 0.55 (95% CI; 0.35, 0.88) for KRAS codon12+13 mutation, 0.69 (95% CI; 0.43, 1.11) for KRAS codon12 mutation, and 0.59 (95% CI; 0.21, 1.64) for KRAS codon13 mutation.</s><s>Furthermore, only the KRAS codon12+13 mutation sub-type group presented discordance of mutation ratio in paired CTCs and primary tumors (P = 0.01 for codon12+13 mutation, P = 0.12 for codon12 mutation, and P = 0.31 for codon13 mutation) (Figure <ref type="figure" target="#fig_1">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pooled data analysis of KRAS sub-type mutation in paired CTCs and primary tumors (stage III)</head><p><s>The pooled ORs of KRAS sub-type mutation of paired CTCs and primary tumors in stage III were 1.19 (95% CI; 0.53, 2.69) for KRAS codon12+13 mutation, 0.91 (95% CI; 0.38, 2.16) for KRAS codon12 mutation, and 6.83 (95% CI; 0.91, 51.00) for KRAS codon13 mutation.</s><s>All three KRAS sub-type groups showed high homogeneity (I 2 = 0) of studies and concordance of mutation ratio in paired CTCs and primary tumor cohorts (test for overall effect P range from 0.06 to 0.82) (Figure <ref type="figure" target="#fig_4">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pooled data analysis of KRAS sub-type mutation in paired CTCs and primary tumors (stage I + II)</head><p><s>The total ORs of KRAS sub-type mutation in paired CTCs and primary tumors at stage I+II were 2.07 (95% CI; 0.71, 6.08) for KRAS codon12+13 mutation, 1.49 (95% CI; 0.43, 5.16) for KRAS codon12 mutation, and 5.68 (95% CI; 0.85, 37.77) for KRAS codon13 mutation.</s><s>However, no statistic divergence was observed in paired CTCs and primary tumors despite high homogeneity in all three KRAS sub-type groups (all I 2 = 0% with P = 0.18 for codon12+13 mutation, P = 0.53 for codon12 mutation and P = 0.07 for codon13 mutation) (Figure <ref type="figure" target="#fig_3">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pooled data analysis of subgroup stratified as enrichment methods of CTC, methods for detecting CTC mutations, and cutoff number of CTCs (stage IV)</head><p><s>We classified the qualifying studies based on enrichment approach of CTCs into a subset of six studies with Epcam-targeted and three without Epcam-targeted CTC enrichment.</s><s>We stratified such subsets for further analysis.</s><s>As a result, ORs in paired CTCs and primary tumors were 0.58 (95% CI: 0.34, 0.99) and 0.47 (95% CI: 0.19, 1.19) for the subsets with and without Epcamtargeted enrichment, respectively.</s><s>We observed low heterogeneity and significant discordance in studies using the Epcam-targeted enrichment approach (I 2 = 0%, P = 0.05) (Figure <ref type="figure" target="#fig_6">6A</ref>).</s><s>In parallel, we divided the methods for detecting mutations in CTCs into PCR-based (OR 0.57, 95% CI: 0.34, 0.96) and pyrosequencing-based (OR 0.45, 95% CI: 0.08, 2.43) subgroups.</s><s>We found low heterogeneity in studies and divergence of KRAS mutation ratio in the PCR-based subgroup (I 2 = 0%, P = 0.04) (Figure <ref type="figure" target="#fig_5">6B</ref>).</s><s>Finally, the cutoff number of CTCs was used to classify the studies as 1-2 CTCs (OR 0.64, 95% CI: 0.37, 1.09) and ≥ 3 CTCs (OR 0.38, 95% CI: 0.16, 0.92) subgroups.</s><s>We found low heterogeneity in studies with significant difference of OR in the ≥ 3 CTCs subgroup (I 2 = 0%, P = 0.03) (Figure <ref type="figure" target="#fig_7">6C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis of BRAF mutation in paired CTCs with primary tumors</head><p><s>A total of 137 cases from four studies were analyzed based on detection of BRAF mutations in paired CTCs with primary tumors of CRC patients.</s><s>The pooled OR was 0.44 (95% CI: 0.14, 1.11); however, we found no difference in paired subgroup populations with high homogeneity between studies (I 2 = 0%, P = 0.08) (Figure <ref type="figure" target="#fig_9">7A</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis of tumor status in CTCs with KRAS mutation</head><p><s>By comparing the differences between the tumor progression and the stable cohorts in CTCs with KRAS mutation, the risk ratio associated with different tumor status was 1.59 (95% CI; 0.69, 3.69).</s><s>We saw no difference     between studies, and measured low heterogeneity (I 2 = 26%, P = 0.28) (Figure <ref type="figure" target="#fig_8">7B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Our meta-analysis compared the discordance of both KRAS and BFRF mutation in paired CTCs with primary tumors from CRC patients.</s><s>Variations in genotype and phenotype between primary tumors and metastasis are effective prognosis biomarkers <ref type="bibr" target="#b15">[15,</ref><ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b41">42]</ref>.</s><s>However, because of lacking specific tumor biomarkers and the limitations of molecular profiling technology for single cell analysis, CTC-related mutations in CRC are still under active investigation.</s><s>Even though numerous studies correlated CTC counts with prognosis, we found here through our meta-analysis of the literature that few mutation-centric CRC studies focus on CTCs.</s><s>From nine studies included, only one study compared KRAS and BRAF mutations in primary tumors, and CTCs and metastatic lesions.</s><s>However, the data of mutations from metastatic lesions were not included in our meta-analysis because no other similar studies were available to carry out statistics <ref type="bibr" target="#b29">[30]</ref>.</s><s>Additional  studies comparing the mutational status of CTCs combined with primary tumors and metastatic lesions are required in future CRC-related analysis.</s></p><p><s>Our findings here revealed discrepancies between KRAS mutations in CTCs and paired primary tumors by pooled meta-analysis.</s><s>Even though high concordance between primary tumors and clinical metastases has been previously demonstrated, discordant sub-populations of genetic mutation intra-tumor or during the metastatic process are commonly reported <ref type="bibr" target="#b10">[10,</ref><ref type="bibr" target="#b14">14,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b42">43]</ref>.</s><s>We grouped individual data drawn from each qualifying study into stage IV, stage III, and stage I + II subgroups.</s><s>We observed high discordance of mutation in CTCs with paired primary tumors in the stage IV and III subgroups, demonstrating that CTCs do not always show genotype agreement with primary lesions, especially in metastatic patients <ref type="bibr" target="#b14">[14,</ref><ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref>.</s><s>However, the limited number of samples from only three studies in the early stage subgroup, as well as few CTCs enriched in peripheral blood, decreased the confidence of our analysis for the stage I + II subgroup.</s><s>Therefore, a larger cohort will be necessary to explore the molecular properties of CTCs and their relationship with primary tumors in CRC patients at early stages.</s><s>Recently, clinical and experimental findings demonstrated that in human CRCs, KRAS codon12 mutations were much more frequent in metastatic than in non-metastatic tumors, and were more aggressive than KRAS codon13 mutation <ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref>.</s><s>Our findings revealed a higher frequency for codon12 mutations than for codon13 mutations in both CTCs (69 cases:14 cases) and primary tumors (84 cases:12 cases), in agreement with previous findings <ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref>.</s><s>Additionally, we found more KRAS mutations in CTCs than in primary tumors at early stage (stage I + II), the same in stage III, but fewer in stage IV.</s><s>This higher frequency of KRAS mutations that we observed in CTCs may correlate with their aggressiveness and resistance to anti-tumor therapy.</s><s>Our analysis demonstrated more KRAS mutations in CTCs than in tumor tissues at an early stage, but lower KRAS mutations in advanced stages of CRC.</s><s>Furthermore, the decrease of KRAS codon12 mutations in CTCs at stage I-II vs stage IV suggested that codon12 mutations may be a more sensitive biomarker for dynamically tracking mutation variation in CTCs.</s></p><p><s>According to recent reports, Epcam-CTC can be more aggressive than Epcam+ CTC, but the EMT process renders Epcam-CTCs undetectable, which decreases the clinical application of molecular profiling for CTC enrichment based on Epcam <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s><s>To decrease selection bias, we performed subgroup analysis based on Epcam expression in stage IV patients.</s><s>The six Epcamtargeted subgroups showed disagreement between CTCs and paired tumor tissues in stage IV patients, suggesting that target Epcam enrichment might be more suitable for identifying aggressive sources of CTCs with mutations than profiles based on size and density gradient.</s><s>A similar result was found through gene sequencing and RT-PCR.</s><s>PCR-based techniques for detecting genetic alterations have been proposed to provide advantages such as high sensitivity and specificity, albeit at a high cost <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref>.</s><s>Low-level mutations sometimes cannot be detected by conventional Sanger sequencing when they are masked by a high background level of wild-type <ref type="bibr" target="#b49">[50]</ref>.</s><s>The ≥ 3 CTCs subgroup showed significant discordance of CTCs with paired tumor tissues, suggesting that increased numbers of CTCs may account for increased mutations.</s><s>Based on our analyses, Epcam-targeted CTC enrichment, PCRbased mutation profiling, and ≥ 3 CTCs enrichment may improve comparisons in mutation variation between CTCs and paired tumor tissues <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b52">53]</ref>.</s><s>In addition to KRAS mutations, BRAF mutations are reported only in 8%-15% of CRC cells and are associated with poor response to anti-EGFR therapy <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b53">54]</ref>.</s><s>We also analyzed discordance of BRAF V600E mutation between CTCs and paired primary CRC tumors but detected no differences.</s><s>Due to the low proportion of BRAF mutation in primary tumors and CTCs, BRAF mutations were not very significant to our meta-analysis.</s><s>Considering the small number of studies included in our analysis, further studies with larger cohorts are warranted.</s></p><p><s>We observed a high concordance of KRAS status was observed in CTCs and primary tumors, contrary to discrepancies reported in previous studies <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37]</ref>.</s><s>We also analyzed clinical stage, mutation sub-type, methods of CTC enrichment, mutation profiling, and cutoff number of CTCs to decrease bias between studies.</s><s>However, certain limitations must be considered when interpreting our results.</s><s>First, only nine studies were included in our meta-analysis, with few samples per study further limiting subgroup analyses.</s><s>Second, each study had insufficient samples regarding various characteristics such as stage, mutation sub-type, cutoff number of CTCs, CTC enrichment methods, and mutation profiling, which yielded few samples in each subgroup.</s><s>However, homogeneity was observed in stage IV subgroups and other KRAS sub-types, suggesting the necessity of subgroup partition based on stage and codon type in future studies.</s><s>Third, publication bias might affect our results even though no significant publication bias was observed in our meta-analysis.</s><s>Despite these limitations, our meta-analysis evaluated the effects of KRAS and BRAF mutation in CTCs of CRC patients by using all qualifications with intensive subgroup analyses.</s><s>Therefore, large sample studies of CRCs focusing on more detailed characteristics are urgently needed to investigate genotype profiling not only regarding mutational variations, but also tumor progression and prognosis.</s><s>In conclusion, our analyses have provided insight into the molecular profiling and genetic detection of mutational variations in paired CTCs and primary tumors.</s><s>We found mutation discordance between CTCs and primary CRCs, particularly in the stage IV and KRAS subgroups.</s><s>Large sample studies stratified by clinical stage and KRAS sub-type are warranted to accurately evaluate mutational variations in CTCs compare to primary and metastatic CRC cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS AND FUNDING</head><p><s>This work was funded by grants from the Medicine and Health Science Research Fund of Zhejiang Province (no.</s><s>2008B021) and the Science Foundation for Fostering Talents of Zhejiang Cancer Hospital (no.</s><s>2012YC008).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>None to declare.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: Diagram for retrieval of studies.</s></p></div></figDesc><graphic coords="3,147.44,309.77,318.80,394.63" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Pooled data analysis of KRAS codon12+13, codon12, codon13 mutation in paired CTCs and primary tumors (stage IV).</s></p></div></figDesc><graphic coords="7,58.34,401.83,496.32,288.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: Analyses of KRAS codon12+13, codon12 and codon13 mutation in paired CTCs and primary tumors (stage I-IV).</s></p></div></figDesc><graphic coords="7,68.13,50.40,476.74,301.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: Pooled data analysis of KRAS codon12+13, codon12, codon13 mutation in paired CTCs and primary tumors (stage I-II).</s></p></div></figDesc><graphic coords="8,65.93,396.00,482.14,291.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: Pooled data analysis of KRAS codon12+13, codon12, codon13 mutation in paired CTCs and primary tumors (stage III).</s></p></div></figDesc><graphic coords="8,71.00,54.85,471.50,282.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6B :</head><label>6B</label><figDesc><div><p><s>Figure 6B: Subgroup analysis based on methods for detecting CTC mutations in paired CTCs and primary tumors (stage IV).</s></p></div></figDesc><graphic coords="9,58.34,461.52,496.32,231.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6A :</head><label>6A</label><figDesc><div><p><s>Figure 6A: Subgroup analysis based on enrichment method of CTC in paired CTCs and primary tumors (stage IV).</s></p></div></figDesc><graphic coords="9,58.34,201.00,496.32,216.02" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 6C :</head><label>6C</label><figDesc><div><p><s>Figure 6C: Subgroup analysis based on cutoff number of CTCs in paired CTCs and primary tumors (stage IV).</s></p></div></figDesc><graphic coords="10,57.84,53.00,496.32,208.86" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 7B :</head><label>7B</label><figDesc><div><p><s>Figure 7B: Data analysis of tumor status in CTCs with KRAS mutation.</s></p></div></figDesc><graphic coords="10,58.68,452.59,496.32,97.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Figure 7A :</head><label>7A</label><figDesc><div><p><s>Figure 7A: Data analysis of BRAF mutation in paired CTCs and primary tumors.</s></p></div></figDesc><graphic coords="10,57.84,310.90,496.32,93.67" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 : Characteristics of studies involved in mutation analysis of CTCs</head><label>1</label><figDesc><div><p><s>According to the UICC Classification of Colorectal Cancer, eight cases (3.28%) were classified as stage I, 24 cases (9.83%) as stage II, 47 cases (19.26 %) as stage III, and stage IV had the majority population with 165 cases (67.62%</s></p></div></figDesc><table><row><cell>First author (year of publication)</cell><cell>1 Buim, M.E (2015)</cell><cell>2 Fabbri, F (2013)</cell><cell>3 Harb, W (2013)</cell><cell>4 Raimondi, C (2014)</cell><cell>5 Kalikaki, A (2014)</cell><cell>6 Lyberopoulou, A (2015)</cell><cell cols="2">7 Mostert, B (2013)</cell><cell>8 Steinert G (2014)</cell><cell>9 N.A (2015) Mohamed Suhaimi,</cell><cell>Total</cell></row><row><cell>Total number</cell><cell>26</cell><cell>40</cell><cell>15</cell><cell>40</cell><cell>31</cell><cell>52</cell><cell>43</cell><cell></cell><cell>28</cell><cell>40</cell><cell>315</cell></row><row><cell>of patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>included</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients' gender</cell><cell>18/8</cell><cell>24/16</cell><cell>11/4</cell><cell>15/25</cell><cell>22/9</cell><cell>33/19</cell><cell>28/15</cell><cell></cell><cell>11/17</cell><cell>19/21</cell><cell>181/134</cell></row><row><cell>(male/female)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tumor location</cell><cell>16 /10</cell><cell>29/11</cell><cell>12/3</cell><cell>28/12</cell><cell>31/0</cell><cell>41/11</cell><cell>26/17</cell><cell></cell><cell>23/5</cell><cell>22/18</cell><cell>228/87</cell></row><row><cell>(colon/rectal)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of</cell><cell>21</cell><cell>16</cell><cell>14</cell><cell>30</cell><cell>23</cell><cell>52</cell><cell>26</cell><cell></cell><cell>22</cell><cell>40</cell><cell>244</cell></row><row><cell>patients with</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CTCs detected</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>IV 21</cell><cell>IV 16</cell><cell>II 4</cell><cell>IV 30</cell><cell>IV 23</cell><cell>II 6</cell><cell>IV 26</cell><cell></cell><cell>III 6</cell><cell>I 8</cell><cell>I 8</cell></row><row><cell>Clinical stage</cell><cell></cell><cell></cell><cell>III 2 IV 8</cell><cell></cell><cell></cell><cell>III 24 IV 22</cell><cell></cell><cell></cell><cell>IV 16</cell><cell>II 14 III 15</cell><cell>II 24 III 47</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>IV 3</cell><cell>IV 165</cell></row><row><cell></cell><cell>After</cell><cell cols="2">Before treatment After</cell><cell>After</cell><cell>After</cell><cell>Before</cell><cell cols="2">Before tumor</cell><cell>Before</cell><cell>After</cell></row><row><cell>sample draws Time of blood</cell><cell>therapy and monoclonal chemotherapy</cell><cell></cell><cell>operation</cell><cell>monoclonal and chemotherapy</cell><cell>monoclonal and chemotherapy</cell><cell>treatment</cell><cell>resection</cell><cell></cell><cell>operation or in the</cell><cell>operation</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>therapy</cell><cell>therapy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cutoff number</cell><cell>2 cells</cell><cell>5 cell</cell><cell>5 cells</cell><cell>1 cell</cell><cell>1 cell</cell><cell>2 cells</cell><cell>3 cells</cell><cell></cell><cell>2 cells</cell><cell>1 cell</cell></row><row><cell>of CTCs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Isolation by size</cell><cell>Density gradient</cell><cell>IsoFlux</cell><cell>CellSearch</cell><cell>CellSearch</cell><cell>Density</cell><cell>CellSearch</cell><cell></cell><cell>CellSearch</cell><cell>Size-based</cell></row><row><cell>Enrichment and antibody staining of CTCs</cell><cell>of epithelial tumors ( ISET) CD45-cells</cell><cell>centrifugation CK +/Hoechst +/ CD45-cells</cell><cell>System EpCAM+ cell</cell><cell>EPCAM+/ CK+/ DAPI +/CD45-cells</cell><cell>EPCAM+/ CK+/ DAPI +/CD45-cells</cell><cell>gradient centrifugation EpCAM+/ Vimentin+/ CK+/CD45-</cell><cell>TM EPCAM+</cell><cell></cell><cell>System EPCAM+/ CK+ cells</cell><cell>filtration unit CK+/ DAPI+/ CD45-cell</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>cells</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell></cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell></row><row><cell></cell><cell>codons12 7/21</cell><cell>codons12 3/16</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell></cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell></row><row><cell>Number of</cell><cell></cell><cell></cell><cell>1/14</cell><cell>6/30</cell><cell>6/23</cell><cell>29/52 codons13</cell><cell>4/26</cell><cell></cell><cell>4/22</cell><cell>9/40</cell><cell>69/244</cell></row><row><cell>mutation in</cell><cell></cell><cell></cell><cell>codons13</cell><cell></cell><cell>codons13</cell><cell>0/52</cell><cell>codons13</cell><cell></cell><cell>codons13</cell><cell>codons13</cell><cell>codons13</cell></row><row><cell>CTCs detected</cell><cell></cell><cell></cell><cell>5/14</cell><cell></cell><cell>1/23</cell><cell>BRAF: 4/52</cell><cell>1/26</cell><cell></cell><cell>2/22</cell><cell>5/40</cell><cell>14/244</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>BRAF: 1/26</cell><cell></cell><cell>BRAF:</cell><cell>BRAF:</cell><cell>BRAF:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1/19</cell><cell>1/40</cell><cell>7/137</cell></row><row><cell></cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell></cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell></row><row><cell></cell><cell>codons12 6/21</cell><cell>codons12 6/16</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell></cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell></row><row><cell>Number of</cell><cell>codons13 3/21</cell><cell>codons13 3/16</cell><cell>1/14</cell><cell>13/30</cell><cell>7/23</cell><cell>26/52 codons13</cell><cell>8/26</cell><cell></cell><cell>8/22</cell><cell>9/40</cell><cell>84/244</cell></row><row><cell>mutation in</cell><cell></cell><cell></cell><cell>codons13</cell><cell></cell><cell>codons13</cell><cell>0/52</cell><cell>codons13</cell><cell></cell><cell>codons13</cell><cell>codons13</cell><cell>codons13</cell></row><row><cell>tissue samples</cell><cell></cell><cell></cell><cell>1/14</cell><cell></cell><cell>1/23</cell><cell>BRAF: 6/52</cell><cell>1/26</cell><cell></cell><cell>1/22</cell><cell>2/40</cell><cell>12/244</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">BRAF: 1/26</cell><cell>BRAF:</cell><cell>BRAF:</cell><cell>BRAF:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3/19</cell><cell>5/ 40</cell><cell>15/137</cell></row><row><cell>Number of</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell><cell></cell><cell>KRAS:</cell><cell>KRAS:</cell><cell>KRAS:</cell></row><row><cell>mutations in</cell><cell>5 cases</cell><cell>2 cases</cell><cell>1 case</cell><cell>2 cases</cell><cell>5 cases</cell><cell>26 cases</cell><cell>4 cases</cell><cell></cell><cell>5 cases</cell><cell>9 cases</cell><cell>59 cases</cell></row><row><cell>both CTC and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>BRAF:</cell><cell>BRAF:</cell><cell>1</cell><cell>BRAF: 1</cell><cell>BRAF:</cell><cell>BRAF:</cell></row><row><cell>tissue samples</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4 cases</cell><cell>case</cell><cell></cell><cell>case</cell><cell>1 case</cell><cell>7 case</cell></row><row><cell></cell><cell>KRAS codons12</cell><cell>KRAS codons12</cell><cell>KRAS</cell><cell>KRAS</cell><cell>KRAS</cell><cell>KRAS</cell><cell>KRAS</cell><cell></cell><cell>KRAS</cell><cell>KRAS</cell></row><row><cell>Subtype</cell><cell>codons13</cell><cell>codons13</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell>codons12</cell><cell></cell><cell>codons12</cell><cell>codons12</cell></row><row><cell>mutation of</cell><cell></cell><cell></cell><cell>codons13</cell><cell>codons13</cell><cell>codons13</cell><cell>codons13</cell><cell>codons13</cell><cell></cell><cell>codons13</cell><cell>codons13</cell></row><row><cell>CTCs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>BRAF (V600E)</cell><cell>BRAF</cell><cell></cell><cell>BRAF</cell><cell>BRAF</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(V600E)</cell><cell></cell><cell>(V600E)</cell><cell>(V600E)</cell></row><row><cell>Methods</cell><cell cols="2">Pyrosequencing Pyrosequencing</cell><cell>castPCR</cell><cell>RT-PCR</cell><cell>PNA-</cell><cell>RFLP assay</cell><cell>nested ASB</cell><cell></cell><cell cols="2">aCGH PCR HRM</cell></row><row><cell>for mutative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>mediated PCR</cell><cell>and ASPCR</cell><cell>PCR</cell><cell></cell><cell></cell><cell>assay and</cell></row><row><cell>detection of</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ASPCR</cell></row><row><cell>CTCs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tumor status</cell><cell>5/16</cell><cell>NA</cell><cell>7/6</cell><cell>NA</cell><cell>6/17</cell><cell>NA</cell><cell>NA</cell><cell></cell><cell>NA</cell><cell>NA</cell><cell>18/39</cell></row><row><cell>(progression/</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>stable)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NOS score</cell><cell>8</cell><cell>8</cell><cell>8</cell><cell>8</cell><cell>9</cell><cell>8</cell><cell>8</cell><cell></cell><cell>8</cell><cell>8</cell><cell>8.11 (mean)</cell></row><row><cell cols="12">NA: not available; castPCR: Competitive Allele-Specific TaqMan PCR; PNA: peptide nucleic acid; RFLP: restriction fragment length polymorphism; nested ASB PCR: nested</cell></row><row><cell cols="12">Allele-Specific Blocker PCR; aCGH PCR: array comparative genomic hybridization PCR; HRM: High resolution melt; ASPCR: Allele-specific PCR; NOS score: Newcastle-</cell></row><row><cell cols="2">Ottawa Scale score.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 : Relationship of KRAS mutation in paired CTCs with tissue samples of CRC patients based on stage III and IV stratification</head><label>2</label><figDesc></figDesc><table><row><cell>Stage IV</cell></row></table><note><p><s>*:indicate P &lt;0.05, NA: not available.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Colorectal cancer statistics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Desantis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="104" to="117" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Phipps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Makar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Win</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Lindor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Newcomb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="1757" to="1764" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Karapetis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khambata-Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Jonker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>O'callaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Tebbutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Simes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chalchal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Shapiro</surname></persName>
		</author>
		<ptr target="www.impactjournals.com/oncotarget" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">K-ras mutations and benefit from cetuximab in advanced colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Robitaille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Au</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="1757" to="1765" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Clinical relevance of KRAS in human cancers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jancík</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drábek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Radzioch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hajdúch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biomed Biotechnol</title>
		<imprint>
			<biblScope unit="page">150960</biblScope>
			<date type="published" when="2010">2010. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Misale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hobor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Scala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Janakiraman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Valtorta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schiavo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buscarino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Siravegna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bencardino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cercek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">486</biblScope>
			<biblScope unit="page" from="532" to="536" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Siena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sartore-Bianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Nicolantonio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Balfour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bardelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="1308" to="1324" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Implications for KRAS status and EGFRtargeted therapies in metastatic CRC</title>
		<author>
			<persName><forename type="first">N</forename><surname>Normanno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tejpar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Morgillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Luca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ciardiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="519" to="527" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">implications for targeted therapies in metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>De Roock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vriendt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Normanno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ciardiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Tejpar</forename><forename type="middle">S</forename><surname>Kras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pik3ca</forename><surname>Braf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="594" to="603" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lipton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gibbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Jorissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Thomson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Usatoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Pick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Carne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1122" to="1130" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Artale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sartore-Bianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Veronese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gambi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Sarnataro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gambacorta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lauricella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Siena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="4217" to="4219" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Diaz</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Berlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bozic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Kinzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Oliner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vogelstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">486</biblScope>
			<biblScope unit="page" from="537" to="540" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schmoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Glimelius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haustermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nordlinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Van De Velde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Balmana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Regula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Nagtegaal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Beets-Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Arnold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2479" to="2516" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Laurent-Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Manceau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Buc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bachet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lecomte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rougier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lievre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Landi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Boige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ducreux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ychou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bibeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="5924" to="5930" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis</title>
		<author>
			<persName><forename type="first">W</forename><surname>De Roock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Claes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Schutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Biesmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fountzilas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kalogeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Kotoula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Papamichael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Laurent-Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Penault-Llorca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rougier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vincenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="753" to="762" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Bihl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Andreozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Foerster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rufle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tornillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Terracciano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Mol Pathol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="14" to="23" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Integrating anti-EGFR therapies in metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Haraldsdottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bekaii-Saab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastrointest Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="285" to="298" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Intratumor heterogeneity: evolution through space and time</title>
		<author>
			<persName><forename type="first">C</forename><surname>Swanton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="4875" to="4882" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cancer heterogeneity: implications for targeted therapeutics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pusztai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Swanton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="479" to="485" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Valladares-Ayerbes M. Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach</title>
		<author>
			<persName><forename type="first">M</forename><surname>Blanco-Calvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Concha</forename><forename type="middle">Á</forename><surname>Figueroa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garrido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="13610" to="13632" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Knijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Mekenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klomp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Vink-Börger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Teerenstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tebar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Riemersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Van Krieken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Punt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Nagtegaal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="1020" to="1026" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Circulating tumor cells: a window into cancer biology and metastasis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Maheswaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Haber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Genet Dev</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="96" to="99" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Khattra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burleigh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Delaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gelmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guliany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Senz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Steidl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">461</biblScope>
			<biblScope unit="page" from="809" to="813" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cancer genomics identifies determinants of tumor biology</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Mardis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">211</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications</title>
		<author>
			<persName><forename type="first">V</forename><surname>Kosmidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Oikonomou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vlassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Avlonitis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Katseli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tsipras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mourtzoukou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kontogeorgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zografos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pintzas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mutat</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="329" to="340" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schneck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blassl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meier-Stiegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Neves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Janni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Neubauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="976" to="986" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Fiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Charbonnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lefebure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Pessot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Frebourg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bauernhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Langer-Freitag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seifert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mauermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Izbicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pantel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Riethdorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<ptr target="www.impactjournals.com/oncotarget28" />
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="252" to="260" />
			<date type="published" when="2008">2008. 2013</date>
		</imprint>
	</monogr>
	<note>Clin Chem.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing</title>
		<author>
			<persName><forename type="first">E</forename><surname>Heitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Auer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lax</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waldispuehl-Geigl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mauermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lackner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Höfler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Eisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="2965" to="2975" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue</title>
		<author>
			<persName><forename type="first">B</forename><surname>Mostert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Sieuwerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bolt-De Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Biermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kraan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lalmahomed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Galen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De Weerd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Spoel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramírez-Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Verhoef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="130" to="141" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs</title>
		<author>
			<persName><forename type="first">F</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ulivi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gallerani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chiadini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Passardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Frassineti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ragazzini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Amadori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="page" from="225" to="231" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay</title>
		<author>
			<persName><forename type="first">W</forename><surname>Harb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Danila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Keys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ionescu-Zanetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="528" to="538" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Steinert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schölch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Niemietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>García</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Voigt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kloor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Rahbari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Büchler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Stoecklein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1694" to="1704" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients</title>
		<author>
			<persName><forename type="first">Mohamed</forename><surname>Suhaimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Foong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Phyo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Cima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">X</forename><surname>Goh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Chia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hillmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="850" to="860" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Buim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Romero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Abdallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Alves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ocea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Mingues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Barbosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Tyng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chojniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Chinen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1289" to="1295" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Raimondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nicolazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gradilone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Falco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chimenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Varriale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Plappert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cortesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gazzaniga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="496" to="503" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kalikaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Politaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Souglakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Apostolaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Papadimitraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Georgoulia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tzardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mavroudis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Georgoulias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Voutsina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e104902</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lyberopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aravantinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Efstathopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nikiteas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bouziotis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Isaakidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Papalois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gazouli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0123902</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Circulating tumor cells: not all detected cells are bad and not all bad cells are detected</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wicha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1508" to="1511" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">and International Stroke Trial Collaborative Group, and European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dinnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sowden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Sakarovitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Petticrew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1" to="173" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Baldus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Engers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hartleb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Stoecklein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Gabbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="790" to="799" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice</title>
		<author>
			<persName><forename type="first">D</forename><surname>Santini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Loupakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vincenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Floriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Canestrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Maltese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Graziano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Baldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Salvatore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1270" to="1275" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFRdirected therapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Oltedal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">G</forename><surname>Aasprong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Møller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kørner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gilje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tjensvoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Birkemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Heikkilä</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smaaland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nordgård</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Colorectal Dis</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1271" to="1277" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorageindependent growth than codon 13 mutation or protooncogene overexpression</title>
		<author>
			<persName><forename type="first">S</forename><surname>Guerrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Casanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Farré</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Capellà</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mangues</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="6750" to="6756" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">K-ras codonspecific mutations produce distinctive metabolic phenotypes in human fibroblasts</title>
		<author>
			<persName><forename type="first">P</forename><surname>Vizan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Boros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Figueras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Capella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mangues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bassilian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cascante</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="5512" to="5515" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Modest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reinacher-Schick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stintzing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tannapfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Laubender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brodowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Knittelfelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vrbanec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schmiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Heinemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zielinski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Drugs</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="666" to="673" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Circulating tumour cells escape from EpCAM-based detection due to epithelial-tomesenchymal transition</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Gorges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tinhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Röse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Zollner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Krahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Von Ahsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">178</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences</title>
		<author>
			<persName><forename type="first">O</forename><surname>Gires</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Stoecklein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="4393" to="4402" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAMbased methodology for basic and clinical cancer research</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Grover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Cummins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Roberts-Thomson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hardingham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1506" to="1516" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Tsiatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Norris-Kirby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Rich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hafez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Gocke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eshleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Diagn</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="425" to="432" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Application of COLD-PCR for improved detection of KRAS mutations in clinical samples</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Chandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Galbincea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Soape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Doan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Barkoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koeppen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Medeiros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Luthra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1023" to="1031" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Peeters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Oliner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Siena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Humblet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Van Laethem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>André</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wiezorek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Reese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Patterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1902" to="1912" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Simi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pratesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vignoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sestini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valanzano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nobili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pazzagli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Orlando</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="247" to="253" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">BRAF mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">X</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Biol Rep</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="2219" to="2223" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
